Total Valuation
bioMerieux has a market cap or net worth of €8.16B. The enterprise value is €7.90K.
Market Cap€8.16B
Enterprise Value€7.90K
Share Statistics
bioMerieux has 118,361,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding118,361,220
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
bioMerieux’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.13%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)9.13%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee273.25K
Profits Per Employee26.69K
Employee Count14,894
Asset Turnover0.73
Inventory Turnover2.01
Valuation Ratios
The current PE Ratio of bioMerieux is 17.6. bioMerieux’s PEG ratio is -4.00.
PE Ratio17.6
PS Ratio3.20
PB Ratio3.17
Price to Fair Value3.17
Price to FCF28.72
Price to Operating Cash Flow9.41
PEG Ratio-4.00
Income Statement
In the last 12 months, bioMerieux had revenue of 4.07B and earned 397.50M in profits. Earnings per share was 3.37.
Revenue4.07B
Gross Profit2.14B
Operating Income561.20M
Pretax Income525.50M
Net Income397.50M
EBITDA999.60M
Earnings Per Share (EPS)3.37
Cash Flow
In the last 12 months, operating cash flow was 907.60M and capital expenditures -322.10M, giving a free cash flow of 585.50M billion.
Operating Cash Flow907.60M
Free Cash Flow585.50M
Free Cash Flow per Share4.95
Dividends & Yields
bioMerieux pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-40.31%
50-Day Moving Average69.84
200-Day Moving Average88.90
Relative Strength Index (RSI)53.70
Average Volume (3m)11.00
Important Dates
bioMerieux upcoming earnings date is Mar 4, 2027, Before Open (Confirmed).
Last Earnings DateJul 28, 2026
Next Earnings DateMar 4, 2027
Ex-Dividend Date―
Financial Position
bioMerieux as a current ratio of 2.39, with Debt / Equity ratio of 9.82%
Current Ratio2.39
Quick Ratio1.48
Debt to Market Cap0.02
Net Debt to EBITDA-0.11
Interest Coverage Ratio35.52
Taxes
In the past 12 months, bioMerieux has paid 128.80M in taxes.
Income Tax128.80M
Effective Tax Rate0.25
Enterprise Valuation
bioMerieux EV to EBITDA ratio is 12.91, with an EV/FCF ratio of 28.48.
EV to Sales3.17
EV to EBITDA12.91
EV to Free Cash Flow28.48
EV to Operating Cash Flow16.37
Balance Sheet
bioMerieux has €657.70M in cash and marketable securities with €421.80M in debt, giving a net cash position of €235.90M billion.
Cash & Marketable Securities€657.70M
Total Debt€421.80M
Net Cash€235.90M
Net Cash Per Share€1.99
Tangible Book Value Per Share€25.24
Margins
Gross margin is 52.04%, with operating margin of 13.79%, and net profit margin of 9.77%.
Gross Margin52.04%
Operating Margin13.79%
Pretax Margin12.91%
Net Profit Margin9.77%
EBITDA Margin24.56%
EBIT Margin13.79%
Analyst Forecast
The average price target for bioMerieux is €76.71, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€76.71
Price Target Upside-15.42% Downside
Analyst ConsensusHold
Analyst Count7
Revenue Growth Forecast-3.18%
EPS Growth Forecast22.52%